TL033 is a drug-Linker conjugates for ADC. TL033 contains a linker and bioactive small molecule toxins. TL033 can conjugate with Sacituzumab antibody (anti Trop-2) for synthesizing BT001021. BT001021 has anti-cancer activities against various cancers, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer.

TL033 TFA is a drug-Linker conjugates for ADC. TL033 TFA contains a linker and bioactive small molecule toxins. TL033 TFA can conjugate with Sacituzumab antibody (anti Trop-2) for synthesizing BT001021. BT001021 has anti-cancer activities against various cancers, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer.

Val-Ala-PAB-SN38 TFA is a drug-linker conjugate for ADC, composed of ADC linker Val-Ala-PAB and SN38, which is the active metabolite of the Topoisomerase I inhibitor Irinotecan

Mal-PEG8-Val-Cit-Exatecan (Compound 1033) is a Drug-Linker Conjugates for ADC, which is composed of Exatecan and a linker. Mal-PEG8-Val-Cit-Exatecan can be used for ADC synthesis.

Fmoc-Val-Lys(Boc)-PAB-Exatecan (Compound 39-7) is a Drug-Linker Conjugates for ADC. Fmoc-Val-Lys(Boc)-PAB-Exatecan consists of the ADC Cytotoxin Exatecan and a linker PAB-Val-Lys-Boc. Fmoc-Val-Lys(Boc)-PAB-Exatecan can be used for synthesis of ADCs.

DBCO-PEG8-VKG-CPT2 is a drug-linker conjugate for ADC. DBCO-PEG8-VKG-CPT2 consists of a topoisomerase 1 inhibitor (7-MAD-MDCPT) and a stable and cleavable linker (DBCO-PEG8-VKG). DBCO-PEG8-VKG-CPT2 can be used for synthesis of ADCs.

DBCO-HS-PEG2-VA-PABC-SG3199 is a drug-linker conjugate for ADC. DBCO-HS-PEG2-VA-PABC-SG3199 consists of a SG3199) based DNA small channel crosslinker and cleavable linker. DBCO-HS-PEG2-VA-PABC-SG3199 can be used for synthesis of ADCs.

DBCO-PEG4-VA-PABC-MMAE is a drug-linker conjugate for ADC. DBCO-PEG4-VA-PABC-MMAE consists of a tubulin inhibitor (MMAE) and a cleavable linker (DBCO-PEG4-VA-PABC). DBCO-PEG4-VA-PABC-MMAE can be used for synthesis of ADC ABBV-400.

RSL3-NH2-Ala-Val-DBCO-PEG4-Maleimide is a drug-linker conjugate for ADC. RSL3-NH2-Ala-Val-DBCO-PEG4-Maleimide consists of a GPX4 inhibitor and ferroptosis inducer (RSL3-NH2) and a linker (H-Ala-Val-OH). RSL3-NH2-Ala-Val-DBCO-PEG4-Maleimide can be used for synthesis of ADCs.

DBCO-PEG3-Glu-VC-PABC-MMAF (compound s19b) is a drug-linker conjugate for ADC by using the tubulin inhibitor, MMAF, linked via cathepsin cleavable DBCO-PEG3-Glu-VC-PABC. DBCO-PEG3-Glu-VC-PABC-MMAF can be used in the synthesis of antibody-drug conjugates (ADCs).

LacNAc-VC-PAB-MMAE is a component of an Antibody-Drug Conjugate (ADC). LacNAc-VC-PAB-MMAE is assembled onto the N-glycosylation site of Trastuzumab by WT Endo-S2.

MCC-AAQ-Exa is a drug-linker conjugates for ADC, obtained by condensing the linker with Exatecan and can be used to prepare antibody-drug conjugates (ADCs). MCC is an ADC linker containing a maleimide fragment.

APL-1082 (exo-EVC-Exatecan) is a drug-Linker conjugate that can be used for ADC synthesis. Its structure contains Exatecan (ADC payload) and linker.

LM-D01 is a Drug-Linker Conjugates for ADC. LM-D01 consists of the ADC Cytotoxin Exatecan-3-amine178265) and a linker MC-GGFG-NH-CH2-O-propionic acid. LM-D01 can be used for synthesis of ADCs.

JSSW-001 is a drug-linker compound applicable for the preparation of antibody-drug conjugates (ADCs). JSSW-001 can be used for the study of cancer.

LD-38 is a drug-linker conjugate for ADC. LD-38 consists of a topoisomerase 1 inhibitor (Exatecan) and a highly hydrophilic stable and cleavable linker. LD-38 can be used for synthesis of ADC.

Aminocaproyl-Val-Cit-PABC-Exatecan TFA is a drug-linker conjugate for ADC, consiting of a cleavable linker (Aminocaproyl-Val-Cit-PABC) and Exatecan(topoisomerase I inhibitor). Aminocaproyl-Val-Cit-PABC-Exatecan TFA can be used for ADC molecues synthesis.

Bis(vinylsulfonyl)piperazine-triazole-PEG3-O-diisopropylsilyl-triptolide is a drug-linker conjugate for ADC. Bis(vinylsulfonyl)piperazine-triazole-PEG3-O-diisopropylsilyl-triptolide consists of a Triptolide and a stable and cleavable linker (Bis(vinylsulfonyl)piperazine-triazole-PEG3-O-diisopropylsilyl-Cl). Bis(vinylsulfonyl)piperazine-triazole-PEG3-O-diisopropylsilyl-triptolide can be used for synthesis of antibody-drug conjugates (ADC).

GDP-Fuc-AM-VcPAB-MMAE is a conjugate of toxic molecules and linkers. GDP-Fuc-AM-VcPAB-MMAE is an important precursor molecule that can be used to prepare ADC drugs. GDP-Fuc-AM-VcPAB-MMAE can be used for cancer research.

Boc-Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC, which is composed of a linker Boc-Val-Cit-PAB (HY141141) and a Microtubule inhibitor MMAE. Boc-Val-Cit-PAB-MMAE can be used for ADC synthesis.

Mal-Val-Lys-PAB-MMAE TFA is a drug-linker conjugate for ADC. Mal-Val-Lys-PAB-MMAE TFA consists of a Tubulin inhibitor (MMAE) and a linker (Mal-Val-Lys-PAB). Mal-Val-Lys-PAB-MMAE TFA can be used for synthesis of ADCs.

Mal-Val-Lys-PAB-MMAE is a drug-linker conjugate for ADC. Mal-Val-Lys-PAB-MMAE consists of a Tubulin inhibitor (MMAE) and a linker (Mal-Val-Lys-PAB). Mal-Val-Lys-PAB-MMAE can be used for synthesis of ADCs.

Aminocaproyl-Val-Cit-PABC-Exatecan is a drug-linker conjugate for ADC, consiting of a cleavable linker (Aminocaproyl-Val-Cit-PABC) and Exatecan(topoisomerase I inhibitor). Aminocaproyl-Val-Cit-PABC-Exatecan can be used for ADC molecues synthesis.

N-Succinimidyl 3-maleimidopropionate (Compound MC1) is a Glucuronide-Gemcitabine conjugate. N-Succinimidyl 3-maleimidopropionate can be used to synthesize ADCs (such as cAc10ec-MC1). N-Succinimidyl 3-maleimidopropionate can be used in Hodgkin's lymphoma research.

Maleimide-Ph(3,5-F)-PEG4-Val-Ala-MF-6 is a drug-linker conjugate for ADC. Maleimide-Ph(3,5-F)-PEG4-Val-Ala-MF-6 consists of a topoisomerase 1 inhibitor (Topi MF-6)175203) and a cleavable linker (Maleimide-Ph(3,5-F)-PEG4-Val-Ala). Maleimide-Ph(3,5-F)-PEG4-Val-Ala-MF-6 can be used for synthesis of ADCs.

4-(3-Tosyl-2-(tosylmethyl)propanoyl)benzoic acid-glu(PEG24-Me)-val-cit-NH-benzyloxyformic acid-MMAE is a drug-linker conjugate for ADC. 4-(3-Tosyl-2-(tosylmethyl)propanoyl)benzoic acid-glu(PEG24-Me)-val-cit-NH-benzyloxyformic acid-MMAE contains a linker and bioactive small molecule toxins MMAE. 4-(3-Tosyl-2-(tosylmethyl)propanoyl)benzoic acid-glu(PEG24-Me)-val-cit-NH-benzyloxyformic acid-MMAE can conjugate with NN2101 (anti c-Kit) for synthesizing NN3201. NN3201 rapidly internalizes and inhibits SCF-driven signaling, thereby delivering its payload to induce cell cycle arrest and apoptosis. NN3201 exhibits significant c-Kit-dependent anti-tumor efficacies in various tumor models, such as small cell lung cancer (SCLC) and gastrointestinal stromal tumor (GIST).

Mc-Lys(PEG12)-Cap-Ala-Ala-PABC-exatecan (compound 12) is a Drug-Linker Conjugate for ADC. Mc-Lys(PEG12)-Cap-Ala-Ala-PABC-exatecan contains the ADC linker (Mc-Lys(PEG12)-Cap-Ala-Ala-PABC) and a DNA topoisomerase I inhibitor Exatecan. Mc-Lys(PEG12)-Cap-Ala-Ala-PABC-exatecan can be used for the development of ADC targeting HER2-positive breast cancer.

MC-VC-PAB-Azide is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

DBCO-S-S-acid is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

m-PEG7-CH2COOH is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).